Key Highlights

  • Lyell Immunopharma (NASDAQ:LYEL) changed hands at USD 15.73 after a 1.91% gain in the latest session, while the screener recorded 42.95% for one week and 72.23% for one month, as of November 5, 2026.
  • Third quarter 2026 figures, published November 4, 2026, showed a net loss of USD 45.5 million compared with USD 38.8 million a year before, and USD 194.0 million in cash at September 30, 2026.
  • The company also disclosed an USD 80.0 million private placement, saying its cash and the new proceeds should carry operations into 2028; the Market Value was roughly USD 382.28 million on 24.51 million shares.
  • Looking further back, the stock is up 12.32% over three months but down 21.10% over six months and 49.79% year to date, with a 52-week range of USD 7.20 to USD 45.00, so the rally sits within a steep decline.

Third Quarter Results and the Placement

Lyell Immunopharma (NASDAQ:LYEL) ended the latest session at USD 15.73, up 1.91%. Its 42.95% weekly and 72.23% monthly advances rank it among the strongest small caps, defined as market values of 300 million to 2 billion USD. The period contains the November 4, 2026 third quarter release. The net loss grew to USD 45.5 million from USD 38.8 million, Research and Development climbed to USD 40.9 million from USD 28.2 million, and general and administrative costs fell to USD 9.3 million from USD 10.7 million. Revenue totaled USD 3 thousand. Cash, equivalents and marketable securities of USD 194.0 million compare with USD 247.2 million at December 31, 2025.

Pivotal Ronde-cel Data Behind the Rebound

The company's own release presents pivotal program data as the leading factor, although no one headline can be linked to the price move. In the PiNACLE study of ronde-cel for third-line and later large B-cell lymphoma, 44 patients were evaluable for efficacy. Overall response reached 91% and complete response 77%; continued complete response was 92% at six months and 75% at twelve months. Cytokine release syndrome at grade 3 or above was not observed, whereas ICANS at grade 3 or above affected 9% of patients. Enrollment is due to complete by year end, pivotal results are anticipated in mid-2027, and a BLA filing is planned for the second half of 2027. The USD 80.0 million raise lengthens the runway into 2028. In broad terms, data, financing and a depressed base often lift small biotech shares.

Valuation Versus Cash and Trading Liquidity

A market value of about USD 382.28 million equals roughly 2 times the USD 194.0 million in cash reported at September 30, 2026, a simple two-number comparison; quarterly non-GAAP net loss was USD 41.3 million. Published coverage lists eight analysts with a Buy consensus and an average target of USD 37.88, which is presented as reported and not as our view. Shares trade USD 29.27 beneath the 52-week high of USD 45.00 and USD 8.53 above the low. A recent intraday reading of 83,379 shares shows light trading, meaning a handful of orders can move the price, spreads may be wide, and reversals are possible.

Where Things Stand

The surge reflects pivotal data, a financing and a heavily sold base, not one clean catalyst. Lyell Immunopharma (NASDAQ:LYEL) ranks among the small cap leaders on both the 1W gain of 42.95% and the 1M gain of 72.23%. Against a 3M gain of 12.32%, a 6M loss of 21.10% and a YTD loss of 49.79%, the stock is recovering within a larger slump. Next checkpoints are the ASH presentations scheduled for December 12 to 15, 2026, enrollment completion and the mid-2027 pivotal readout.